生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
IMFINZI
® (
durvalumab
) plus chemotherapy further improved overall survival benefit in
advanced biliary tract cancer
in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
2022-09-12
·
BioSpace
合作
小分子药物
抗体
First in Class
免疫疗法
Sept. 12, 2022 15:05 UTC HIMALAYA Phase III trial exploratory results support the benefit of
tremelimumab
added to
IMFINZI
in
unresectable liver cancer
regardless of etiology WILMINGTON, Del.--(BUSINESS WIRE)-- Updated results from the TOPAZ-1 Phase III trial showed
AstraZeneca
’s
IMFINZI
® (
durvalumab
), in combination with standard-of-care chemotherapy demonstrated a clinically meaningful and durable overall survival (OS) benefit as a treatment for patients with
advanced biliary tract cancer (BTC)
. These results from
TOPAZ-1
, the first Phase III trial to show improved OS with an immunotherapy combination in this setting, will be presented today at the European Society for Medical Oncology (ESMO) Congress 2022 in Paris (abstract #56P). The updated results for
IMFINZI
plus chemotherapy (
gemcitabine
plus
cisplatin
) showed enhanced clinical efficacy after an additional 6.5 months of follow-up, demonstrating a 24% reduction in the risk of death versus chemotherapy alone (based on an HR of 0.76; 95% CI, 0.64–0.91). Updated median OS was 12.9 months versus 11.3 with chemotherapy. More than two times as many patients were estimated to be alive at two years versus chemotherapy alone (23.6% versus 11.5%). Results were seen across all prespecified subgroups, regardless of disease status,
tumor
location or
PD-L1
expression. In addition, OS benefit was observed in patients whose
tumors
stayed the same size (stable disease) as well as in patients whose
tumors
got smaller or disappeared (responders). The safety pro
IMFINZI
plus chemotherapy continued to be well-tolerated, with no new safety signals observed with longer follow-up. Grade 3 or 4 treatment-related AEs were experienced by 60.9% of patients treated with
IMFINZI
and chemotherapy, and by 63.5% of patients receiving chemotherapy alone.
IMFINZI
plus chemotherapy did not increase the discontinuation rate due to adverse events (AEs) compared to chemotherapy alone (8.9% for the
IMFINZI
combination versus 11.4% for chemotherapy). Do-Youn Oh, MD, PhD, Professor, Division of Medical Oncology, Department of Internal Medicine at
Seoul National University Hospital
and Seoul National University College of Medicine, and principal investigator in the TOPAZ-1 Phase III trial, said: “It's exciting to see the improved overall survival delivered by
durvalumab
plus chemotherapy over the current standard of care for patients with
advanced biliary tract cancer
after a median follow-up of nearly two years. With limited treatment advances over the past decade, these patients have long faced a dismal prognosis. For the first time, an immunotherapy-based combination has shown the ability to alter the course of treatment for this disease and should become the new standard of care.” Susan Galbraith, Executive Vice President, Oncology R&D,
AstraZeneca
said: “These longer-term data reinforce the survival benefit and well-tolerated safety
pro IMFINZI
added to standard-of-care chemotherapy for patients with
advanced biliary tract cancer
. With these results, the exploratory data from the HIMALAYA trial and the recent FDA approval based on the TOPAZ-1 trial, we are continuing to advance our commitment to extend survival for patients with
gastrointestinal tumors
who desperately need new treatment options.” Summary of updated results:
TOPAZ-1 IMFINZI
+ chemotherapy (N=341) Chemotherapy (n=344) OSi,ii Median OS (95% CI) (in months) 12.9 11.3 HR (95% CI)iii 0.76 (0.64, 0.91) OS rate at 12 months (95% CI) (%)iv 54.3 47.1 OS rate at 24 months (95% CI) (%) 23.6 11.5 OS by BoRv,vi Median OS (95% CI), responders, months 19.5 15.7 HR (95% CI) respondersiii 0.69 (0.46, 1.04) Median OS (95%
CI
), stable disease (SD), months 13.6 11.5 HR (95% CI) SDiii 0.77 (0.62, 0.96) 12-month OS rate in responders (95%
CI
) (%)iv 75.8 75.0 12-month OS rate in SD (95% CI) (%)iv 57.5 48.0 24-month OS rate in responders (95% CI) (%)iv 40.6 20.5 24-month OS rate in SD (95% CI) (%)iv 20.7 10.6 6.5 months of additional follow-up (data cut-off: 25 February 2022) after the primary analysis, with 76.9% overall OS event maturity At data cut-off for this analysis, median (95% CI) follow-up time (calculated using the inverse Kaplan-Meier techniques with the censoring indicator of OS reversed) was 23.4 (20.6–25.2) months for
IMFINZI
plus chemotherapy and 22.4 (21.4–23.8) months for chemotherapy HRs were calculated using a Cox proportional hazards model. OS rates calculated using Kaplan-Meier techniques To avoid immortal time bias, only participants surviving ≥ 3 months were included in this OS by best objective response analysis BoR was assessed by the investigator per Response Evaluation Criteria In
Solid Tumors
(RECIST) v1.1 in all randomized participants with measurable disease at baseline and defined as response (complete response or partial response), SD or progressive disease (PD); BoR was determined based on the IA data cut-off (11 August 2021) Earlier this month,
IMFINZI
in combination with chemotherapy was granted approval in the US as a treatment for adults with locally advanced or metastatic BTC based on results from
TOPAZ-1
. Regulatory applications are also currently under review in Europe, Japan and several other countries based on the TOPAZ-1 results. In October 2021, the TOPAZ-1 trial met the OS primary endpoint at a predefined interim analysis, reducing the risk of death by 20% versus chemotherapy (based on a hazard ratio [HR] of 0.80; 95% confidence interval [CI], 0.66-0.97; 2-sided p=0.021). HIMALAYA Phase III trial exploratory analysis by aetiology in
unresectable hepatocellular carcinoma
at ESMO Also at ESMO, an exploratory analysis from the HIMALAYA Phase III trial evaluated the impact of disease causes on outcomes for patients with
unresectable hepatocellular carcinoma
(abstract #714P). Data from HIMALAYA suggest a trend for OS benefit over
sorafenib
with the STRIDE regimen regardless of the underlying disease cause (hepatitis B virus [HBV], hepatitis C virus [HCV] or nonviral). Similar trends were observed with
IMFINZI
versus
sorafenib
across subsets. In 2021, positive results from the HIMALAYA Phase III trial showed a single priming dose of
tremelimumab
, an
anti-CTLA4 antibody
, added to
IMFINZI
(STRIDE regimen) demonstrated a statistically significant and clinically meaningful improvement in OS versus
sorafenib
as a 1st-line treatment for patients with
unresectable hepatocellular carcinoma (HCC)
who had not received prior systemic therapy and were not eligible for localized treatment. When subsets were adjusted for prognostic factor imbalances, patients with HBV treated with the STRIDE regimen experienced a 36% reduction in the risk of death versus
sorafenib
(based on a HR of 0.64, 95% CI 0.47-0.86). Median duration of response was 25.69 months versus 17.00 months for
sorafenib
. Patients with HCV treated with the STRIDE regimen experienced an 11% reduction in the risk of death versus
sorafenib
(based on a HR of 0.89; 95% CI 0.63-1.25). Median duration of response was 13.5 months versus 15.7 months for
sorafenib
. Nonviral patients treated with the STRIDE regimen experienced a 23% reduction in the risk of death versus
sorafenib
(based on a HR of 0.77; 95% CI 0.59-1.00). Median duration of response was 13.21 months versus 6.01 months for
sorafenib
. The safety profiles of STRIDE and
durvalumab
were consistent across etiology subgroups. In the past,
viral HCC
(disease associated with
cirrhosis
related to
chronic hepatitis B
or
hepatitis C
) has been the primary etiology of the disease. Over the last two decades, the prevalence of
non-viral HCC
(disease associated with non-viral factors including
liver disease
,
obesity
and
diabetes
) has significantly increased. HIMALAYA is the only Phase III trial to demonstrate a survival benefit for immunotherapy in participants with non-viral HCC.1,2 The STRIDE regimen is under review by global regulatory authorities in
unresectable HCC
based on the results of the HIMALAYA trial. IMPORTANT SAFETY INFORMATION There are no contraindications for
IMFINZI
® (
durvalumab
). Immune-Mediated Adverse Reactions Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatal immune-mediated reactions. Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting treatment or after discontinuation. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including
infection
. Institute medical management promptly, including specialty consultation as appropriate. Withhold or permanently discontinue
IMFINZI
depending on severity. See Dosing and Administration for specific details. In general, if
IMFINZI
requires interruption or discontinuation, administer systemic
corticosteroid
therapy (1 mg to 2 mg/kg/day
prednisone
or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate
corticosteroid
taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with
corticosteroid
therapy.
Immune-Mediated Pneumonitis
IMFINZI
can cause
immune-mediated pneumonitis
. The incidence of
pneumonitis
is higher in patients who have received prior thoracic radiation. In patients who did not receive recent prior radiation, the incidence of
immune-mediated pneumonitis
was 2.4% (34/1414), including fatal (<0.1%), and Grade 3-4 (0.4%) adverse reactions. In patients who received recent prior radiation, the incidence of
pneumonitis
(including
radiation pneumonitis
) in patients with
unresectable Stage III NSCLC
following definitive chemoradiation within 42 days prior to initiation of
IMFINZI
in PACIFIC was 18.3% (87/475) in patients receiving
IMFINZI
and 12.8% (30/234) in patients receiving placebo. Of the patients who received
IMFINZI
(475), 1.1% were fatal and 2.7% were Grade 3 adverse reactions. The frequency and severity of
immune-mediated pneumonitis
in patients who did not receive definitive chemoradiation prior to
IMFINZI
were similar in patients who received
IMFINZI
as a single agent or with
ES-SCLC
or BTC when in combination with chemotherapy.
Immune-Mediated
Immune-Mediated Colitis
IMFINZI
can cause
immune-mediated colitis
that is frequently associated with
diarrhea
.
Cytomegalovirus (CMV) infection
/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.
Immune-mediated colitis
occurred in 2% (37/1889) of patients receiving
IMFINZI
, including Grade 4 (<0.1%) and Grade 3 (0.4%) adverse reactions.
Immune-Mediated Hepatitis
IMFINZI
can cause
immune-mediated hepatitis
.
Immune-mediated hepatitis
occurred in 2.8% (52/1889) of patients receiving
IMFINZI
, including fatal (0.2%), Grade 4 (0.3%) and Grade 3 (1.4%) adverse reactions.
Immune-Mediated Endocrinopathies
Adrenal Insufficiency:
IMFINZI
can cause
primary or secondary adrenal insufficiency
. For Grade 2 or higher
adrenal insufficiency
, initiate symptomatic treatment, including hormone replacement as clinically indicated.
Immune-mediated adrenal insufficiency
occurred in 0.5% (9/1889) of patients receiving
IMFINZI
, including Grade 3 (<0.1%) adverse reactions.
Hypophysitis
:
IMFINZI
can cause
immune-mediated hypophysitis
.
Hypophysitis
can present with acute symptoms associated with mass effect such as
headache
,
photophobia
, or visual field cuts.
Hypophysitis
can cause
hypopituitarism
. Initiate symptomatic treatment including hormone replacement as clinically indicated. Grade 3
hypophysitis
/
hypopituitarism
occurred in <0.1% (1/1889) of patients who received
IMFINZI
.
Thyroid Disorders
:
IMFINZI
can cause
immune-mediated thyroid disorders
.
Thyroiditis
can present with or without
endocrinopathy
.
Hypothyroidism
can follow
hyperthyroidism
. Initiate hormone replacement therapy for
hypothyroidism
or institute medical management of
hyperthyroidism
as clinically indicated.
Thyroiditis
:
Immune-mediated thyroiditis
occurred in 0.5% (9/1889) of patients receiving
IMFINZI
, including Grade 3 (<0.1%) adverse reactions.
Hyperthyroidism
:
Immune-mediated hyperthyroidism
occurred in 2.1% (39/1889) of patients receiving
IMFINZI
.
Hypothyroidism
:
Immune-mediated hypothyroidism
occurred in 8.3% (156/1889) of patients receiving
IMFINZI
, including Grade 3 (<0.1%) adverse reactions.
Type 1 Diabetes Mellitus
, which can present with
diabetic ketoacidosis
: Monitor patients for
hyperglycemia
or other signs and symptoms of
diabetes
. Initiate treatment with
insulin
as clinically indicated. Grade 3
immune-mediated type 1 diabetes mellitus
occurred in <0.1% (1/1889) of patients receiving
IMFINZI
.
Immune-Mediated Nephritis
with
Renal Dysfunction
IMFINZI
can cause
immune-mediated nephritis
.
Immune-mediated nephritis
occurred in 0.5% (10/1889) of patients receiving
IMFINZI
, including Grade 3 (<0.1%) adverse reactions. Immune-Mediated Dermatology Reactions
IMFINZI
can cause
immune-mediated rash
or
dermatitis
.
Exfoliative dermatitis
, including
Stevens-Johnson Syndrome (SJS)
,
drug rash
with
eosinophilia
and
systemic symptoms (DRESS)
, and
toxic epidermal necrolysis (TEN)
, have occurred with
PD-1/L-1
blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate
non-exfoliative rashes
.
Immune-mediated rash
or
dermatitis
occurred in 1.8% (34/1889) of patients receiving
IMFINZI
, including Grade 3 (0.4%) adverse reactions. Other Immune-Mediated Adverse Reactions The following clinically significant, immune-mediated adverse reactions occurred at an incidence of less than 1% each in patients who received
IMFINZI
or were reported with the use of other
PD-1/PD-L1
blocking antibodies. Cardiac/vascular:
Myocarditis
,
pericarditis
,
vasculitis
. Nervous system:
Meningitis
,
encephalitis
,
myelitis
and
demyelination
,
myasthenic syndrome
/
myasthenia gravis
(including exacerbation),
Guillain-Barré syndrome
, nerve paresis, autoimmune neuropathy. Ocular:
Uveitis
,
iritis
, and other ocular inflammatory toxicities can occur. Some cases can be associated with
retinal detachment
. Various grades of
visual impairment
to include
blindness
can occur. If
uveitis
occurs in combination with other immune-mediated adverse reactions, consider a
Vogt-Koyanagi-Harada-like syndrome
, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss. Gastrointestinal:
Pancreatitis
including increases in serum
amylase
and
lipase
levels,
gastritis
,
duodenitis
. Musculoskeletal and
connective tissue disorders
:
Myositis
/
polymyositis
,
rhabdomyolysis
and associated sequelae including
renal failure
,
arthritis
, polymyalgia rheumatic. Endocrine:
Hypoparathyroidism
Other (hematologic/immune):
Hemolytic anemia
,
aplastic anemia
,
hemophagocytic lymphohistiocytosis
,
systemic inflammatory response syndrome
,
histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis)
,
sarcoidosis
,
immune thrombocytopenia
, solid organ transplant rejection. Infusion-Related Reactions
IMFINZI
can cause severe or life-threatening infusion-related reactions. Monitor for signs and symptoms of infusion-related reactions. Interrupt, slow the rate of, or permanently discontinue
IMFINZI
based on the severity. See Dosing and
Administration
for specific details. For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses. Infusion-related reactions occurred in 2.2% (42/1889) of patients receiving
IMFINZI
, including Grade 3 (0.3%) adverse reactions. Complications of Allogeneic HSCT after
IMFINZI
Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a
PD-1/L-1
blocking antibody. Transplant-related complications include
hyperacute graft-versus-host-disease (GVHD)
,
acute GVHD
,
chronic GVHD
,
hepatic veno-occlusive disease (VOD)
after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between
PD-1/L-1
blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a
PD-1/L-1
blocking antibody prior to or after an allogeneic HSCT. Embryo-Fetal Toxicity Based on its mechanism of action and data from animal studies,
IMFINZI
can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. In females of reproductive potential, verify pregnancy status prior to initiating
IMFINZI
and advise them to use effective contraception during treatment with
IMFINZI
and for at least 3 months after the last dose of
IMFINZI
. Lactation There is no information regarding the presence of
IMFINZI
in human milk; however, because of the potential for adverse reactions in breastfed infants from
IMFINZI
, advise women not to breastfeed during treatment and for at least 3 months after the last dose. Adverse Reactions In patients with locally advanced or metastatic BTC in the TOPAZ-1 study receiving
IMFINZI
(n=338), the most common adverse reactions (occurring in ≥20% of patients) were
fatigue
,
nausea
,
constipation
,
decreased appetite
,
abdominal pain
,
rash
, and
pyrexia
In patients with locally advanced or metastatic BTC in the TOPAZ-1 study receiving
IMFINZI
(n=338), discontinuation due to adverse reactions occurred in 6% of the patients receiving
IMFINZI
plus chemotherapy. Serious adverse reactions occurred in 47% of patients receiving
IMFINZI
plus chemotherapy. The most frequent serious adverse reactions reported in at least 2% of patients were
cholangitis
(7%),
pyrexia
(3.8%),
anemia
(3.6%),
sepsis
(3.3%) and
acute kidney injury
(2.4%). Fatal adverse reactions occurred in 3.6% of patients receiving
IMFINZI
plus chemotherapy. These include
ischemic or hemorrhagic stroke
(4 patients),
sepsis
(2 patients),
upper gastrointestinal hemorrhage
(2 patients) The safety and effectiveness of
IMFINZI
have not been established in pediatric patients. Indication:
IMFINZI
, in combination with
gemcitabine
and
cisplatin
, is indicated for the treatment of adult patients with
locally advanced or metastatic biliary tract cancer (BTC)
. Please see complete Prescribing Information, including Medication Guide. Notes
Biliary tract cancer
BTC
is a group of rare and aggressive
gastrointestinal (GI) cancers
that form in the cells of the bile ducts (
cholangiocarcinoma
), gallbladder or ampulla of Vater (where the bile duct and pancreatic duct connect to the small intestine).3,4
Cholangiocarcinoma
is more common in China and South-East Asia and is on the rise in Western countries.3,5
Gallbladder cancer
is more common in certain regions of South America, India and Japan.7 Early-stage BTC affecting the bile ducts and gallbladder often presents without clear symptoms and most new cases of BTC are therefore diagnosed at an advanced stage, when treatment options are limited and the prognosis is poor.5,7,8 TOPAZ-1
TOPAZ-1
is a randomized, double-blind, placebo controlled, multicenter, global Phase III trial of
IMFINZI
in combination with chemotherapy (
gemcitabine
plus
cisplatin
) versus placebo in combination with chemotherapy as a 1st-line treatment in 685 patients with unresectable advanced or metastatic BTC including
intrahepatic and extrahepatic cholangiocarcinoma
, and
gallbladder cancer
. Patients with
ampullary carcinoma
were excluded. The primary endpoint is overall survival and key secondary endpoints included progression-free survival, objective response rate and safety. The trial was conducted in 105 centers across 17 countries including in the US, Europe, South America and several countries in Asia including South Korea, Thailand, Japan and China. HIMALAYA HIMALAYA was a randomized, open-label, multicenter, global Phase III trial of
Imfinzi
monotherapy and the STRIDE regimen, comprising a single priming dose of
tremelimumab
300mg added to
IMFINZI
1500mg followed by
IMFINZI
every four weeks versus
sorafenib
, a standard-of-care
multi-kinase inhibitor
. The trial included a total of 1,324 adult patients with
unresectable HCC
who had not been treated with prior systemic therapy and were not eligible for locoregional therapy (treatment localized to the liver and surrounding tissue). The trial was conducted in 190 centers across 16 countries, including in the US, Canada, Europe, South America and Asia. The primary endpoint was OS for STRIDE versus
sorafenib
and key secondary endpoints included OS for
IMFINZI
versus
sorafenib
, objective response rate and progression-free survival (PFS) for STRIDE and for
IMFINZI
alone.
IMFINZI
®
IMFINZI
® (
durvalumab
) is a human monoclonal antibody that binds to the
PD-L1
protein and blocks the interaction of
PD-L1
with the
PD-1
and
CD80
proteins, countering the
tumor
’s immune-evading tactics and releasing the inhibition of immune responses. In addition to the approval in BTC,
IMFINZI
is the only approved immunotherapy in the curative-intent setting of
unresectable, Stage III non-small cell lung cancer (NSCLC)
in patients whose disease has not progressed after chemoradiotherapy and is the global standard of care in this setting based on the PACIFIC Phase III trial.
IMFINZI
is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of
extensive-stage small cell lung cancer (ES-SCLC)
based on the CASPIAN Phase III trial. In 2021, updated results from the CASPIAN trial showed
IMFINZI
plus chemotherapy tripled patient survival at three years versus chemotherapy alone.
IMFINZI
is also approved for previously treated patients with
advanced bladder cancer
in several countries. Since the first approval in May 2017, more than 100,000 patients have been treated with
IMFINZI
. As part of a broad development program,
IMFINZI
is being tested as a single treatment and in combinations with other anti-
cancer
treatments for patients with
SCLC
,
NSCLC
,
bladder cancer
, several
GI cancers
,
ovarian cancer
,
endometrial cancer
, and other
solid tumors
.
IMFINZI
combinations have demonstrated clinical benefit in multiple additional
cancer
settings with positive Phase III trials in
unresectable advanced liver cancer
(HIMALAYA) and
metastatic NSCLC
(POSEIDON).
AstraZeneca
in
GI cancers
AstraZeneca
has a broad development program for the treatment of
GI cancers
across several medicines and a variety of
tumor
types and stages of disease. In 2020,
GI cancers
collectively represented approximately 5.1 million new
cancer
cases leading to approximately 3.6 million deaths.6 Within this program, the Company is committed to improving outcomes in gastric, liver, BTC,
esophageal, pancreatic, and colorectal cancers
.
IMFINZI
is being assessed in combinations in liver, BTC,
esophageal and gastric cancers
in an extensive development program spanning early to late-stage disease. The Company aims to understand the potential of
fam-trastuzumab deruxtecan-nxki
, a
HER2-directed
antibody drug conjugate, in the two most common
GI cancers
,
colorectal and gastric cancers
.
Fam-trastuzumab
deruxtecan-nxki
is jointly developed and commercialized by
AstraZeneca
and
Daiichi Sankyo
.
Olaparib
is a first-in-class
PARP inhibitor
PARP
inhibitor with a broad and advanced clinical trial program across multiple
GI tumor
types including
pancreatic and colorectal cancers
.
Olaparib
is developed and commercialized in collaboration with
Merck & Co
., Inc., known as
MSD
outside the US and Canada.
AstraZeneca
in immunotherapy Immunotherapy is a therapeutic approach designed to stimulate the body’s immune system to attack
tumors
. The Company’s Immuno-Oncology (IO) portfolio is anchored in immunotherapies that have been designed to overcome evasion of the anti-
tumor
immune response.
AstraZeneca
is invested in using IO approaches that deliver long-term survival for new groups of patients across
tumor
types. The Company is pursuing a comprehensive clinical-trial program that includes
IMFINZI
as a single treatment and in combination with
tremelimumab
and other novel antibodies in multiple
tumor
types, stages of disease, and lines of treatment, and where relevant using the
PD-L1
biomarker as a decision-making tool to define the best potential treatment path for a patient. In addition, the ability to combine the IO portfolio with radiation, chemotherapy, and targeted small molecules from across
AstraZeneca
’s oncology pipeline, and from research partners, may provide new treatment options across a broad range of
tumors
.
AstraZeneca
in oncology
AstraZeneca
is leading a revolution in oncology with the ambition to provide cures for
cancer
in every form, following the science to understand
cancer
and all its complexities to discover, develop and deliver life-changing medicines to patients. The Company's focus is on some of the most challenging
cancers
. It is through persistent innovation that
AstraZeneca
has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca
has the vision to redefine
cancer
care and, one day, eliminate
cancer
as a cause of death. About
AstraZeneca
AstraZeneca
is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in
Oncology
, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK,
AstraZeneca
operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @AstraZenecaUS. References Toyoda H, et al. Improved survival of
viral hepatocellular carcinoma
but not
non-viral hepatocellular carcinoma
from 2000 to 2020: A multi-centre cohort study of 6007 patients from high-volume academic centres in Japan. Aliment Pharmacol Ther. 2022; 56: 694– 701. Hamed MA, et al. Non-viral factors contributing to
hepatocellular carcinoma
. World J Hepatol. 2013 Jun 27;5(6):311-22. Marcano-Bonilla L, et al.
Biliary tract cancers
: epidemiology, molecular pathogenesis and genetic risk associations. CCO. 2016;5(5). ESMO. What is
Biliary Tract Cancer
. Available at: . Accessed September 2022. Turkes F, et al. Contemporary Tailored Oncology Treatment of
Biliary Tract Cancers
. Gastroenterol Res Pract. 2019:7698786. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for
Breast Cancer
V2.2022. © National
Comprehensive Cancer Network, Inc.
Cancer
Network, Inc. 2022. All rights reserved. Accessed September 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Rawla P, et al. Epidemiology of
gallbladder cancer
. Clin Exp Hepatol. 2019;5(2):93-102. Banales JM, et al.
Cholangiocarcinoma
2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. US-68341 Last Updated 08/22
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Ci Medical Co., Ltd.
英群企业股份有限公司
Daiichi Sankyo Co., Ltd.
[+6]
适应症
放射性肺炎
肾上腺皮质功能不全
胆管炎
[+104]
靶点
PDL1
PD-1
amylase
[+4]
药物
度伐利尤单抗
曲美木单抗
Retro-1
[+11]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务